Identification
- Generic Name
- AT-527
- DrugBank Accession Number
- DB16451
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- AT527
- External IDs
- AT-527
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
AT-527 is a prodrug of a guanosine nucleotide analog which has the potential to potently inhibit the in vitro replication of SARS-CoV-2. It also inhibits the NS5B polymerase in the Hepatitis C Virus. This drug is currently being investigated against COVID-19 and has also been investigated against Hepatitis C infections.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Acids
- Acids, Noncarboxylic
- Experimental Unapproved Treatments for COVID-19
- Guanine Nucleotides
- Heterocyclic Compounds, Fused-Ring
- Nucleic Acids, Nucleotides, and Nucleosides
- Nucleotides
- Organophosphorus Compounds
- Phosphate salts
- Phosphoric Acids
- Phosphorus Acids
- Phosphorus Compounds
- Purine Nucleotides
- Purines
- Ribonucleotides
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- DAI4WL7JQ6
- CAS number
- 2241337-84-6
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Berliba E, Bogus M, Vanhoutte F, Berghmans PJ, Good SS, Moussa A, Pietropaolo K, Murphy RL, Zhou XJ, Sommadossi JP: Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrob Agents Chemother. 2019 Sep 30. pii: AAC.01201-19. doi: 10.1128/AAC.01201-19. [Article]
- Good SS, Moussa A, Zhou XJ, Pietropaolo K, Sommadossi JP: Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020 Jan 8;15(1):e0227104. doi: 10.1371/journal.pone.0227104. eCollection 2020. [Article]
- External Link [Link]
- Roche announcement. [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 3 Suspended Treatment Coronavirus Disease 2019 (COVID‑19) 1 3 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Completed Treatment Chronic Hepatitis C Virus (HCV) Infection / Hepatitis C Virus (HCV) Infection / Hepatitis C Virus Infection 1 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) 1 1 Completed Treatment Chronic Hepatitis C Virus (HCV) Infection / Hepatitis C Virus (HCV) Infection 1 1 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / Healthy Volunteer Study 1 1 Completed Treatment Healthy Volunteer Study 7 1 Completed Treatment Healthy Volunteers Study 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at January 21, 2021 01:43 / Updated at February 13, 2021 10:53